Frederiksberg, Denmark

Anette Gundertofte

USPTO Granted Patents = 1 


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Anette Gundertofte - A Pioneer in Therapeutic Innovations

Introduction

Anette Gundertofte, based in Frederiksberg, Denmark, is a noteworthy inventor whose contributions to the field of pharmaceuticals are pivotal. With a keen focus on developing therapeutic compounds, her work has potential implications for managing significant health challenges.

Latest Patents

Anette holds a patent for a novel class of compounds known as 11β-hydroxysteroid dehydrogenase type 1 active compounds. This patent describes compounds of general formula (I) and discusses their application in therapy, pharmaceutical compositions comprising these compounds, and their manufacturing for medicinal use. These compounds play a crucial role in modulating the activity of 11β-HSD1, making them beneficial in treating conditions such as metabolic syndrome.

Career Highlights

Anette Gundertofte’s career is marked by her dedication to research and innovation in pharmacology. Her work at High Point Pharmaceuticals, LLC exemplifies her commitment to developing therapeutic solutions that address crucial health dilemmas. The innovative nature of her patent illustrates her expertise and contributes to advancements in medical treatment.

Collaborations

Throughout her career, Anette has collaborated with esteemed professionals in her field, including Anker S. Jorgensen and Gita Camilla Tejlgaard Kampen. These partnerships have fostered a collaborative environment conducive to innovation, enabling the development of impactful therapeutic breakthroughs.

Conclusion

Anette Gundertofte's contributions reflect the essence of innovation in the pharmaceutical landscape. Her singular patent and collaboration with industry experts spotlight her role in advancing health care solutions that can significantly impact the treatment of metabolic diseases. As she continues her work at High Point Pharmaceuticals, her ongoing efforts promise to lead to further groundbreaking developments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…